EBMT 2022 | Perspectives on allogeneic NK cell-based immunotherapy
Monika Holubová, PhD, Charles University Faculty of Medicine, Pilsen, Czech Republic, talks on strategies to improve allogeneic natural killer (NK) cell-based immunotherapy for the treatment of hematological malignancies. Indeed, whilst allogeneic NK cells are currently being evaluated in many clinical trials, intents to use them to target tumors have not been successful. It is necessary to improve the culture conditions of healthy donor NK cells to enhance the expression of activation molecules and improve NK cell persistence. According to Dr Holubová, it is also necessary to combine NK cells with other available agents and tools to enhance the efficacy of NK cell-based immunotherapy. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
